Forte Biosciences (FBRX) Payables (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Payables of $13.1 million for Q1 2026, up 160.48% year-over-year from $5.0 million in Q1 2025, and up 30.98% quarter-over-quarter from $10.0 million in Q4 2025.
Forte Biosciences (FBRX) Payables (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Payables for 11 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 160.48% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (up 160.48% YoY), while the FY2025 annual figure was $10.0 million, up 104.73% from the prior year.
- Payables advanced to $13.1 million in Q1 2026 per FBRX's latest filing, from $10.0 million in the prior quarter.
- Across five years, Payables topped out at $13.1 million in Q1 2026 and bottomed at $576000.0 in Q1 2022.
- Historically, Payables has averaged $4.2 million across 5 years, with a median of $4.9 million in 2024.
- Annual changes were most pronounced in 2022 — Payables slumped 48.88% — and 2023, when it jumped 349.54%.
- Forte Biosciences' Payables stood at $1.2 million in 2022, then rose by 23.5% to $1.4 million in 2023, then surged by 242.63% to $4.9 million in 2024, then surged by 104.73% to $10.0 million in 2025, then jumped by 30.98% to $13.1 million in 2026.
- Business Quant data shows FBRX's Payables at $13.1 million in Q1 2026, $10.0 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.01 Mn |
| Mar 31, 2026 | 13.08 Mn |
| Dec 31, 2025 | 9.99 Mn |
| Sep 30, 2025 | 5.49 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 5.02 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Sep 30, 2024 | 5.16 Mn |
| Jun 30, 2024 | 5.28 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 5.35 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 698,000.00 |
| Mar 31, 2022 | 576,000.00 |
| Dec 31, 2021 | 946,000.00 |
| Sep 30, 2021 | 2.33 Mn |